Advertisement

Effect of Dihydropyridine Calcium Channel Modulators on Isolated Peripheral and Cerebral Vessels

  • R. Towart
  • S. Kazda
  • B. Lamp
  • G. Thomas
  • M. Schramm
Part of the Bayer-Symposium book series (BAYER-SYMP, volume 9)

Abstract

The pioneering work by Fleckenstein and his group [1,2] has firmly established the concept of the calcium antagonistic drugs. The most potent and specific calcium antagonists are the dihydropyridines (DHP) [3, 4] such as nifedipine and its analogues nitrendipine and nimodipine. Their actions have been discussed in numerous recent reviews, and are the subject of this volume.

Keywords

Calcium Antagonist Basilar Artery Calcium Influx Cerebral Vessel Peripheral Vessel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17:49–66.CrossRefGoogle Scholar
  2. 2.
    Fleckenstein A (1983) Calcium antagonism in heart and smooth muscle. John Wiley & Sons, New York.Google Scholar
  3. 3.
    Vater W, Kroneberg G, Hoffmeister F, Kaller H, Meng K, Oberdorf A, Puls W, Schloßmann K, Stoepel K (1972) Zur Pharmakologie von 4-(2-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-diacarbonsauredimethylester (Nifedipine, BAY a1040). Arzneim Forsch 22:1–14.Google Scholar
  4. 4.
    Loev B, Goodman MM, Snoder KM, Tedeschi R, Macho E (1974) “Hantzch-Type” dihydropyridine hypotensive agents 3. J Med Chem 17:956–965.PubMedCrossRefGoogle Scholar
  5. 5.
    German Pat. Applic DOS 3130041 (1981).Google Scholar
  6. 6.
    Takenaka T, Maeno H (1982) A vasoconstrictive compound 1,4-dihydropyridine derivative. Proc. Jap. Parmacol. Soc, Abstract 213.Google Scholar
  7. 7.
    Truog AG, Branner H, Criscione T, Falbert M, Kuhnis H, Meier M, Rogg H (1984) CGP 28392, a dihydropyridine Ca-entry stimulator. In: Rubin, RP, Weiss GB and Putney JW (eds) Calcium in biological systems. Plenum Press, New York.Google Scholar
  8. 8.
    Groß R, Bechem M, Kayser M, Schramm M, Taniel R, Thomas G (1984) Effects of the Ca+ +-agonistic dihydropyridine BAY K8644 on the heart. This volume.Google Scholar
  9. 9.
    Schramm M, Thomas G, Towart R, Franckowiak G (1983 b) Activation of calcium channels by novel 1,4-dihydropyridines. Arzneim Forsch (Drug Res) 33:1268–1272.Google Scholar
  10. 10.
    Schramm M, Towart R (1984) Modulation of calcium influx by the 1,4-dihydropyridines nifedipine and BAY K8644 (submitted for publication).Google Scholar
  11. 11.
    Ruegg JC, Meisheri K, Pfitzner G, Zeugner C (1983) Skinned coronary smooth muscle: calmodulin, calcium antagonists and cAMP influence contractility. Bas Res Cardiol 78:462–471.CrossRefGoogle Scholar
  12. 12.
    Towart R (1981). The selective inhibition of serotonin-induced contractions of rabbit cerebral vascular smooth muscle by calcium antagonistic dihydropyridines: An investigation of the mechanism of action of nimodipine. Circ Res 48:650–647.PubMedGoogle Scholar
  13. 13.
    Towart R (1982) A new method for investigating the isometric contractile responses of small blood vessels. Brit J Pharmacol 75:150P.Google Scholar
  14. 14.
    Schramm M, Towart R (1983) Modulation of calcium channel function with the 1,4-dihydropyridine structure. J Physiol 349:53P.Google Scholar
  15. 15.
    Schramm M, Thomas G, Towart R, Franckowiak G (1983a) Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature 303:535–537.PubMedCrossRefGoogle Scholar
  16. 16.
    Schramm M, Towart R, Kazda S, Thomas G, Franckowiack G (1984) Calcium-agonism, a new mechanism for positive inotropy: haemodynamic effects and mode of action of BAY K8644. Adv Myocardiol 6:59–70.Google Scholar
  17. 17.
    Massingham R (1973) A study of compounds which inhibit vascular smooth muscle contraction. Eur J Pharmacol 22:75–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Schuemann HJ, Goerlitz BD, Wagner J (1975) Influence of papaverine, D600 and nifedipine on the effects of noradrenaline and calcium on the isolated aorta and mesenteric artery of the rabbit. Naunyn Schmiedebergs Arch Pharmacol 289:409–418.CrossRefGoogle Scholar
  19. 19.
    Towart R (1982) Effects of nitrendipine (BAY e5009), nifedipine, verapamil, phentolamine, papaverine, and minoxidil on contractions of isolated rabbit aortic smooth muscle. J Cardiovasc Pharmacol 4:895–902.PubMedCrossRefGoogle Scholar
  20. 20.
    Freedman SB, Miller RJ, Miller DM, Tindall DR (1984) Interactions of maitotoxin with voltage-sensitive calcium channels in cultured neuronal cells. Proc Natl Acad Sci USA 81:4582–4585.PubMedCrossRefGoogle Scholar
  21. 21.
    Garcia AG, Sala F, Reig JA, Viniegra S, Frias J, Fonteriz R, Gandia L (1984) Dihydropyridine BAY K8644 activates chromaffin cell calcium channels. Nature 309:69–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Albus U, Habermann E, Ferry DR, Glossmann H (1984) Novel 1,4-dihydropyridine (BAY K8644) facilitates calcium-dependent (3H)-noradrenaline release from PC12 cells. J. Neurochem. 42:1186–1189.PubMedCrossRefGoogle Scholar
  23. 23.
    Thomas G, Metzger G (1984) The effects of BAY K8644, a positive inotropic dihydropyridine, in the guinea-pig papillary muscle. IUPHAR 9th Int. Cong. Pharmacol. 1984, Abstract 23.Google Scholar
  24. 24.
    Satoh K, Wada Y, Taira N (1984) Differential effects of BAY K8644 a presumed calcium channel activator, on sinoatrial nodel and ventricular automaticity of the dog heart. N-S Arch Pharmacol 326:190–192.CrossRefGoogle Scholar
  25. 25.
    Enyeart JJ, Hinkle PM (1984) The calcium agonist BAY K8644 stimulates secretion from a pituitary cell line. Biochem Biophys Res Comm 122:991–996.PubMedCrossRefGoogle Scholar
  26. 26.
    Lee KS, Tsien RW (1983) Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature 302:790–794.PubMedCrossRefGoogle Scholar
  27. 27.
    Kass RS (1982) Nisoldipine, a new more selective calcium current blocker in cardiac Purkinje fibres. J Pharmacol Exp Ther 223:446–456.PubMedGoogle Scholar
  28. 28.
    Sangunetti MC, Kass RS (1984). Regulation of cardiac calcium current and contractile activity by the dihydropyridine BAY K8644 is voltage dependent. J Mol Cell Cardiol 16:667–671.CrossRefGoogle Scholar
  29. 29.
    Spedding M, Berg C (1984) Interaction between a “calcium agonist” BAY K8644 and calcium antagonists differentiate between calcium antagonist subgroups (to be published).Google Scholar
  30. 30.
    Glossmann H, Linn T, Rombusch M, Ferry DR (1983) Temperature dependent regulation of d-cis-(3H)-diltiazem binding to Ca channels by 1,4-dihydropyridine channel agonists and antagonists. FEBS Let 160:226–232.CrossRefGoogle Scholar
  31. 31.
    Janis RS, Rampe D, Sarmiento JG, Triggle DJ (1984) Specific binding of a calcium channel activator, 3(H)BAY K8644, to membranes from cardiac muscle and brain. Biochem Biophys Res Comm 121:317–323.PubMedCrossRefGoogle Scholar
  32. 32.
    Belleman P (1984) Binding properties of a novel calcium channel activating dihydropyridine in monolayer cultures of beating monocytes. FEBS Let 167:88–92.CrossRefGoogle Scholar
  33. 33.
    Godfraind T (1983) Actions of nifedipine on calcium fluxes and contraction in isolated rat arteries. J Pharmacol Exp Ther 224:433–450.Google Scholar
  34. 34.
    Calvin RS, Pearson N, Messineo FC, Katz AM (1982) Effects of Ca channel blockers in Ca transport and Ca ATPase in skeletal and cardiac sarcoplasmic reticulum vesicles. J Cardiovasc Pharmacol 4:935–941.CrossRefGoogle Scholar
  35. 35.
    Pan M, Janis RA (1984). Effect of calcium antagonists on Na+,K+-AT Pase of smooth muscle. Biochem Pharmacol 33:787–791.PubMedCrossRefGoogle Scholar
  36. 36.
    Janis RA, Scriabine A (1983) Site of action of Ca channel inhibitors. Biochem Pharmacol 32:3499–3507.PubMedCrossRefGoogle Scholar
  37. 37.
    Schwartz A, Triggle DJ (1984) Cellular action of calcium channel blocking drugs. Ann Rev Med 35:325–339.PubMedCrossRefGoogle Scholar
  38. 38.
    Spedding M (1983) Direct inhibitory effects of some calcium antagonists and trifluoroparazine on the contractile proteins in smooth muscle. Brit J Pharmacol 79:225–231.Google Scholar
  39. 39.
    Kanmura Y, Itoh T, Suzuki H, Ito Y, Kuriyama H (1983) Nifedipine actions on smooth muscle cells of pig and rabbit skinned and intact coronary arteries. In: Hashimoto K, Kawai C (eds) Asian Pacific Adalat-Symposium Tokyo, pp 3-30.Google Scholar
  40. 40.
    Kreye VAW, Ruegg JC, Hoffman F (1983) Effects of calcium-antagonist and calmodulin-antagonist drugs in calmodulin-dependent contractions of chemically skinned vascular smooth muscle from rabbit renal arteries. N-S Arch Pharmacol 323:85–89.CrossRefGoogle Scholar
  41. 41.
    Thomas G, Gross R, Pfitzner G, Ruegg JC (1984) The positive inotropic dihydropyridine BAY K8644 does not affect calcium sensitivity or calcium release of skinned cardiac fibres. N-S Arch Pharmacol 328:378–381.CrossRefGoogle Scholar
  42. 42.
    Movesian MA, Adelstein RS (1984) Inhibition of turkey gizzard myosin light chain kinase activity by BAY K8644. Eur J Pharmacol 103:161–163.CrossRefGoogle Scholar
  43. 43.
    Harder DR (1983) Heterogeneity of membrane properties in vascular muscle from various beds. Fed Proc 42:253–256.PubMedGoogle Scholar
  44. 44.
    Towart R, Wehinger E, Meyer H, Kazda S (1982) The effects of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle. Arzneim Forsch (Drug Res) 32:338–346.Google Scholar
  45. 45.
    Allen GS, Banghart SB (1979) Cerebral arterial spasm. Part 9: in vitro effects of nifedipine on serotonin phenylephrine and potassium induced contractions of canine basilar and femoral arteries. Neurosurgery 4:37–41.PubMedCrossRefGoogle Scholar
  46. 46.
    Shimizu K, Ohta T, Toda N (1980) Evidence for greater susceptibility of isolated dog cerebral arteries to Ca antagonists than peripheral arteries. Stroke 11:261–266.PubMedCrossRefGoogle Scholar
  47. 47.
    Yamamoto H, Hwang O, van Breemen C (1984) BAY K8644 differentiates between potential and receptor operated Ca2+-channels. Eur J Pharmacol 102:555–557.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • R. Towart
  • S. Kazda
  • B. Lamp
  • G. Thomas
  • M. Schramm

There are no affiliations available

Personalised recommendations